PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth while GNPX reduces spending. John Neff would investigate strategic advantage.
34.62%
G&A growth 50-75% of GNPX's 52.68%. Bruce Berkowitz would examine operational efficiency.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while GNPX shows 0.00% growth. Joel Greenblatt would examine efficiency.
14.45%
Similar operating expenses growth to GNPX's 17.95%. Walter Schloss would investigate norms.
14.45%
Similar total costs growth to GNPX's 17.95%. Walter Schloss would investigate norms.
561.32%
Interest expense change of 561.32% while GNPX maintains costs. Bruce Berkowitz would investigate control.
-26.41%
Both companies reducing D&A. Martin Whitman would check industry patterns.
55.40%
EBITDA growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth above 1.5x GNPX's 46.73%. Michael Burry would check for concerning trends.
43.33%
Pre-tax income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense change of 561.32% while GNPX maintains burden. Bruce Berkowitz would investigate strategy.
43.33%
Net income growth while GNPX declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth 1.25-1.5x GNPX's 34.62%. Bruce Berkowitz would examine sustainability.
43.35%
Diluted EPS growth 1.25-1.5x GNPX's 34.62%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.